BMY 14802

BMY 14802 is a small-molecule investigational drug originally developed as a potential atypical antipsychotic. It acts primarily as a selective sigma receptor antagonist and also displays agonistic activity at the 5-HT1A (serotonin 1A) receptor, with some affinity for 5-HT2 and D4 dopamine receptors. Unlike typical antipsychotics, it was found not to induce extrapyramidal symptoms in preclinical models, and it was hypothesized to function through regionally selective, indirect modulation of dopaminergic systems via its action at sigma sites. BMY 14802 went through clinical development for schizophrenia and other central nervous system indications but was discontinued before approval. The compound also demonstrated effects in animal models relevant to Parkinson’s disease and neuroprotection, exhibiting the ability to suppress abnormal involuntary movements (AIMs) in L-DOPA-induced dyskinesia.

Other names

alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol